trending Market Intelligence /marketintelligence/en/news-insights/trending/f6kvcabsl_y0bpwcimsizq2 content esgSubNav
In This List

LivaNova medical implant receives US FDA clearance for treating heart condition

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


LivaNova medical implant receives US FDA clearance for treating heart condition

LivaNova PLC said the U.S. Food and Drug Administration granted 510(k) clearance to its medical implant Memo 4D, a semi-rigid ring used for treating a type of heart condition.

The London-based medical device maker said the Memo 4D is a semi-rigid mitral annuloplasty ring to treat mitral regurgitation, a disorder of the heart in which the mitral valve does not close properly when the heart pumps out blood.

Mitral valve annuloplasty is a surgical technique for the repair of leaking mitral valves.